Minnesota bills · 2025-2026 Regular Session
Minnesota HF 4852
Formulary Committee members with a potential conflict of interest permitted to participate in committee communications and discussions, commissioner of human services required to develop a public comment process for recommendations, and committee required to seek expertise from the Minnesota Rare Disease Advisory Council.
- Introduced
- In committee
- Passed House
- Passed Senate
- To Governor
- Became law
Sponsors
- Reyer (Democratic-Farmer-Labor)
Cosponsors (1)
- Bierman (Democratic-Farmer-Labor)
Summary
No official summary is available for this bill.
Latest action(Apr 7, 2026): Introduction and first reading, referred to Health Finance and Policy
Text versions
- Introduction· Apr 6, 2026
Roll-call votes
No recorded votes on this bill.
Actions
- Apr 7, 2026 · House
Introduction and first reading, referred to Health Finance and Policy